July/August

Ivosidenib for Relapsed/Refractory Acute Myeloid Leukemia

July 22, 2019

Clinical Insights

On July 20, 2018, the FDA approved ivosidenib (Tibsovo) as a treatment option for adult patients with relapsed/refractory acute myeloid leukemia, specifically with a mutation in the IDH1 gene.

Creative Financing for Innovative, Curative Therapies

July 22, 2019

Features

States are getting inventive in their approaches to meeting the health care needs of their citizens, especially when it comes to curative treatments for conditions that have a high prevalence rate.

Distributors Reveal the Road Map to Successful Specialty Therapy Launches

July 22, 2019

Features

A strong partnership can support the successful commercialization of a product, position the therapy to meet a manufacturer’s business goals, and provide patients with an option to improve their health and quality of life.

Experts Discuss Best Treatment Practices and Emerging Therapies for Axial Spondyloarthritis

July 22, 2019

Disease State Management

In a Specialty Pharmacy Times® Insights video series, experts Atul A. Deodhar, MD, and Hillary Norton, MD, discussed clinical best practices surrounding the diagnosis, management, and treatment of AxSpA, including an overview of available therapies.